Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

THERMO FISHER SCIENTIFIC

(TMO)
  Report
Delayed Nyse  -  04:00 2022-12-09 pm EST
560.23 USD   -1.36%
12/08Thermo Fisher Scientific : Expands its Global Biologics and Steriles Manufacturing Capabilities in China
PU
12/07Thermo Fisher Scientific Launches TrueMark Infectious Disease Research Panels
AQ
12/07RBC Initiates Thermo Fisher Scientific at Outperform With $660 Price Target, Cites 'Advantageous Position'
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Thermo Fisher Scientific Inc. Showcases New Clinical and Research Lab Solutions At AACC 2022

07/25/2022 | 08:00am EST

Thermo Fisher Scientific Inc. is showcasing innovative diagnostic technologies, assays and a complement of solutions for researchers developing new diagnostics. During the 74th American Association for Clinical Chemistry Annual Scientific Meeting and Clinical Laboratory Exposition (AACC 2022), being held at the McCormick Place Convention Center in Chicago, July 24–28, Thermo Fisher is exhibiting within booth #1413. Enabling Clinical Research Lab Agility and Responsiveness: The Applied Biosystems TaqMan-SARS-CoV-2 Mutation Panel enables labs to build their own custom panel from a menu of verified real-time PCR assays.

This meets the evolving needs of customers and public health agencies seeking to rapidly identify and survey current mutations as well as emerging variants. To support labs as they move beyond COVID testing, Thermo Fisher is evolving its respiratory testing menu and improving automation to accelerate research. The Applied Biosystems TaqPath COVID-19, Flu A, Flu B Combo Kit helps labs expand their existing COVID-19 testing menu for respiratory samples while maintaining workflow simplicity and without increasing operational costs.

Also featured at AACC is the new Thermo Scientific KingFisher SpeciTRAX Sample Transfer System, which provides researchers in infectious diseases and genetics with an automated sample-handling system, including new features, such as an automated decapper, that relieve the sample processing bottleneck for increased throughput. A new interface with the Inpeco S.A.'s FlexLab Total Laboratory Automation system (TLA), enables primary tubes on the Inpeco LAS to be transported directly to the Thermo Scientific Cascadion SM Clinical Analyzer for automated loading, pre-treatment and analysis. This first-of-its-kind integration enables fully automated, gold-standard LC-MS/MS technology to improve clinical lab productivity.

New Technology and Assays: The Thermo Scientific DRI Fentanyl II Drugs of Abuse Assay is now available on medium to high-throughput instruments, including the Indiko Plus and Mindray BS-480, Mindray BA-800M. Labs of any size can now accurately test for multiple drugs of abuse at high volume using fully automated analyzers. Thermo Fisher's broad and complementary offering of screening to confirmatory solutions also includes the Thermo Scientific Tox Explorer Collection, an all-in-one LC-MS/MS solution for toxicology.

Enhanced Allergy and Autoimmune Testing: The Thermo Scientific EliA RNA Pol III and EliA Rib-P tests have received U.S. FDA clearance for aiding in the diagnosis of Systemic Sclerosis and Systemic Lupus Erythematosus. These tests are part of a broader EliA portfolio of connective tissue disease tests that help provide a clearer clinical picture for patients.


ę S&P Capital IQ 2022
All news about THERMO FISHER SCIENTIFIC
12/08Thermo Fisher Scientific : Expands its Global Biologics and Steriles Manufacturing Capabil..
PU
12/07Thermo Fisher Scientific Launches TrueMark Infectious Disease Research Panels
AQ
12/07RBC Initiates Thermo Fisher Scientific at Outperform With $660 Price Target, Cites 'Adv..
MT
12/07Thermo Fisher Scientific Inc. Announces FDA Grants De Novo Classification to HLA Typing..
CI
12/06Thermo Fisher Scientific Raises Greenhouse Gas Emissions Reduction Target on Path to Ne..
BU
12/06Thermo Fisher Scientific Launches TrueMark Infectious Disease Research Panels
CI
11/29Transcript : Thermo Fisher Scientific Inc. Presents at 5th Annual Evercore IS..
CI
11/29Barclays Cuts Price Target on Thermo Fisher to $570 From $575, Maintains Overweight Rat..
MT
11/21Thermo Fisher Scientific Issues 1.25 Billion Euros of 2026, 2034 Notes
MT
11/21Thermo Fisher Scientific Inc. : Entry into a Material Definitive Agreement, Other Events, ..
AQ
More news
Analyst Recommendations on THERMO FISHER SCIENTIFIC
More recommendations
Financials (USD)
Sales 2022 43 901 M - -
Net income 2022 6 919 M - -
Net Debt 2022 24 827 M - -
P/E ratio 2022 32,4x
Yield 2022 0,21%
Capitalization 224 B 224 B -
EV / Sales 2022 5,66x
EV / Sales 2023 5,54x
Nbr of Employees 130 000
Free-Float 88,9%
Chart THERMO FISHER SCIENTIFIC
Duration : Period :
Thermo Fisher Scientific Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends THERMO FISHER SCIENTIFIC
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Last Close Price 567,95 $
Average target price 617,84 $
Spread / Average Target 8,78%
EPS Revisions
Managers and Directors
Marc N. Casper Chairman, President & Chief Executive Officer
Stephen Williamson Chief Financial Officer & Senior Vice President
Ryan Snyder Chief Information Officer & Senior Vice President
Alan B. Sachs Chief Medical Officer
Karen E. Nelson Chief Scientific Officer
Sector and Competitors